Immuneering Corporation IMRX
3.76 USD +0.08 (+2.17%)
At closeNov 4, 2026, 4:02 PM EST
3.76 0.00 0.00%
After hours · Nov 4, 4:02 PM ET
3.70 Day range 3.87
3.38 52-week range 8.48
- YTD
- -42.86%
- 1 year
- -41.07%
- Market cap
- 243.51M
- EPS (ttm)
- -0.92
- Shares out
- 31.05M
- Forward P/E
- -1.34
- YTD return
- -42.86%
- 1-year return
- -41.07%
- Volume
- 730.60K
- Avg volume
- 720.63K
- Open
- 3.74
- Previous close
- 3.68
- Day's range
- 3.70 – 3.87
- 52-week range
- 3.38 – 8.48
- Beta
- -0.40
- Analysts
- Buy
- Price target
- 12.42 (+230.2%)
- Earnings date
- Aug 6, 2024
2Y +1.80 (+91.84%)
Key statistics
- Enterprise value
- 2.11M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -31.61M
- Total cash
- 59.73M
- Total debt
- 4.31M
- Return on equity
- -61.81%
- Short % of float
- 9.27%
- 50-day average
- 2.01
- 200-day average
- 1.84
Analyst view
Consensus: buy
Buy
Price target (mean) 12.42 +230.2% upside
Now 3.76
- Target (low)
- 1.50
- Target (mean)
- 12.42
- Target (high)
- 25.00
Ratings (0m) 7 5 buy · 1 hold · 1 sell
- Strong buy2
- Buy3
- Hold1
- Sell1
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.39167.
Financials — quick view
IMRX Revenue — quarterly 0
IMRX Net income — quarterly -24.19M
IMRX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.54 | -0.49 | +0.05 | +9.26% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | -0.47 | +0.04 | +7.84% |
| Aug 6, 2024 | Jun 1, 2024 | -0.51 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.45 | -0.49 | -0.04 | -8.89% |
| May 7, 2024 | Mar 1, 2024 | -0.45 | — | — | — |
| Mar 1, 2024 | Dec 1, 2023 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | Needham | reit | Buy | Buy |
| Sep 13, 2024 | Needham | reit | Buy | Buy |
| Aug 7, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 7, 2024 | Needham | reit | Buy | Buy |
| May 8, 2024 | Needham | reit | Buy | Buy |
About Immuneering Corporation
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immuneering.com
News
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference 
Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium 
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates 
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer 
Immuneering to Present at the ESMO Congress 2026 
Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX 
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development 
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
Your note
Sign in to keep a note on IMRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERMAN ANN E | Director | Purchase | Mar 17, 2024 | 67,465 |
| BOOKMAN MICHAEL | Officer | Stock Award(Grant) | Mar 14, 2024 | 3,850 |
| BRAKEWOOD HAROLD EUGENE | Officer | Purchase | Mar 21, 2024 | 3,900 |
| CORMORANT ASSET MANAGEMENT ,L.P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 31, 2024 | 0 |
| FEINBERG PETER | Director | Purchase | Mar 21, 2024 | 1,096,060 |
| HALL BRETT MATTHEW | Officer | Purchase | Mar 19, 2024 | 345,896 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.45% | 1,070,322 | 2.35M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 2.61% | 810,127 | 1.78M | Sep 29, 2024 |
| Morgan Stanley | 1.45% | 449,311 | 988.48K | Sep 29, 2024 |
| Blackrock Inc. | 1.03% | 318,419 | 700.52K | Sep 29, 2024 |
| Millennium Management Llc | 0.79% | 246,270 | 541.79K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.68% | 209,641 | 461.21K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.37% | 736,188 | 1.62M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.64% | 509,134 | 1.12M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.93% | 289,196 | 636.23K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 118,328 | 260.32K | Oct 30, 2024 |
| ETF Series Solutions-Range Cancer Therapeutics ETF | 0.21% | 64,035 | 140.88K | Aug 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 49,849 | 109.67K | Oct 30, 2024 |